Effectiveness of Switching Biologics for Severe Asthma Patients in Japan: A Single-Center Retrospective Study

Persistent Asthma from Childhood to Adulthood Presents a Distinct Phenotype of Adult Asthma

(2020) Masako To et al.   Journal of Allergy and Clinical Immunology-In Practice

Real-World Effectiveness and the Characteristics of a “Super-Responder” to Mepolizumab in Severe Eosinophilic Asthma

(2020) Joanne E. Kavanagh et al.   CHEST

Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study

(2020) Takanori Numata et al.   BMC Pulmonary Medicine

Multidimensional assessment of asthma identifies clinically relevant phenotype overlap: a cross-sectional study

(2020) Yu Yu Han et al.   Journal of Allergy and Clinical Immunology-In Practice

Dupilumab Improves Asthma Control and Lung Function in Patients with Insufficient Outcome During Previous Antibody Therapy

(2020) Carlo Mümmler et al.   Journal of Allergy and Clinical Immunology-In Practice

The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma

(2019) Kenneth R. Chapman et al.   ALLERGY

Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility

(2019) Marc Humbert et al.   RESPIRATORY MEDICINE

Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials

(2019) Claus Bachert et al.   LANCET

Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis

(2019) Takanori Numata et al.   BMC Pulmonary Medicine

Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma

(2018) Bradley E. Chipps et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study

(2018) Marc Humbert et al.   EUROPEAN RESPIRATORY JOURNAL

Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma

(2018) Klaus F. Rabe et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma

(2018) Mario Castro et al.   NEW ENGLAND JOURNAL OF MEDICINE

Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies

(2018) J Mark FitzGerald et al.   Lancet Respiratory Medicine

Subphenotypes of type 2 severe asthma in adults

(2018) Masako Matsusaka et al.   Journal of Allergy and Clinical Immunology-In Practice

Anti–IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison

(2018) William Busse et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Comparative Efficacy of Anti IL-4, IL-5 and IL-13 Drugs for Treatment of Eosinophilic Asthma: A Network Meta-analysis

(2018) Imran H. Iftikhar et al.   LUNG

Matching-adjusted indirect comparison of benralizumab versus interleukin-5 inhibitors for the treatment of severe asthma: a systematic review

(2018) Arnaud Bourdin et al.   EUROPEAN RESPIRATORY JOURNAL

Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma

(2017) Parameswaran Nair et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparative effectiveness of mepolizumab and omalizumab in severe asthma: An indirect treatment comparison

(2017) Sarah M. Cockle et al.   RESPIRATORY MEDICINE

Japanese guidelines for adult asthma 2017

(2017) Masakazu Ichinose et al.   ALLERGOLOGY INTERNATIONAL

Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment

(2016) A. Magnan et al.   ALLERGY

Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial

(2016) Eugene R Bleecker et al.   LANCET

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial

(2016) J Mark FitzGerald et al.   LANCET

The Xolair Pregnancy Registry (EXPECT): The safety of omalizumab use during pregnancy

(2015) Jennifer Namazy et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

The prevalence of severe refractory asthma

(2015) Pieter-Paul W. Hekking et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma

(2014) Elisabeth H. Bel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma

(2014) Hector G. Ortega et al.   NEW ENGLAND JOURNAL OF MEDICINE

Exploring the Effects of Omalizumab in Allergic Asthma

(2013) Nicola A. Hanania et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

(2012) Ian D Pavord et al.   LANCET

Time Trend in the Prevalence of Adult Asthma in Japan: Findings from Population-Based Surveys in Fujieda City in 1985,1999, and 2006

(2011) Yuma Fukutomi et al.   ALLERGOLOGY INTERNATIONAL

The minimally important difference of the Asthma Control Test

(2009) Michael Schatz et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY